TargetTyrosine-protein kinase receptor(Homo sapiens (Human))
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Affinity DataIC50: 0.170nMAssay Description:A recombinant retrovirus was created from expression plasmid FLAG-EML4-ALKv1/pMX-iresCD8 in which cDNA for EMLA-ALK fusion protein v1 was integrated,...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase receptor(Homo sapiens (Human))
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Affinity DataIC50: 0.210nMAssay Description:A recombinant retrovirus was created from expression plasmid FLAG-EML4-ALKv1/pMX-iresCD8 in which cDNA for EMLA-ALK fusion protein v1 was integrated,...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase receptor(Homo sapiens (Human))
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Affinity DataIC50: 0.220nMAssay Description:A recombinant retrovirus was created from expression plasmid FLAG-EML4-ALKv1/pMX-iresCD8 in which cDNA for EMLA-ALK fusion protein v1 was integrated,...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase receptor(Homo sapiens (Human))
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Affinity DataIC50: 0.230nMAssay Description:A recombinant retrovirus was created from expression plasmid FLAG-EML4-ALKv1/pMX-iresCD8 in which cDNA for EMLA-ALK fusion protein v1 was integrated,...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase ROS(Homo sapiens (Human))
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Affinity DataIC50: 0.230nMAssay Description:A partial protein of only a kinase domain of ROS protein was purchased from Carna Biosciences Inc., Japan, and tests were conducted as in Test Exampl...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase receptor(Homo sapiens (Human))
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Affinity DataIC50: 0.240nMAssay Description:A recombinant retrovirus was created from expression plasmid FLAG-EML4-ALKv1/pMX-iresCD8 in which cDNA for EMLA-ALK fusion protein v1 was integrated,...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase receptor(Homo sapiens (Human))
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Affinity DataIC50: 0.260nMAssay Description:A recombinant retrovirus was created from expression plasmid FLAG-EML4-ALKv1/pMX-iresCD8 in which cDNA for EMLA-ALK fusion protein v1 was integrated,...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase receptor(Homo sapiens (Human))
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Affinity DataIC50: 0.260nMAssay Description:A recombinant retrovirus was created from expression plasmid FLAG-EML4-ALKv1/pMX-iresCD8 in which cDNA for EMLA-ALK fusion protein v1 was integrated,...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase receptor(Homo sapiens (Human))
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Affinity DataIC50: 0.260nMAssay Description:A recombinant retrovirus was created from expression plasmid FLAG-EML4-ALKv1/pMX-iresCD8 in which cDNA for EMLA-ALK fusion protein v1 was integrated,...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase ROS(Homo sapiens (Human))
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Affinity DataIC50: 0.290nMAssay Description:A partial protein of only a kinase domain of ROS protein was purchased from Carna Biosciences Inc., Japan, and tests were conducted as in Test Exampl...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase receptor(Homo sapiens (Human))
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Affinity DataIC50: 0.330nMAssay Description:A recombinant retrovirus was created from expression plasmid FLAG-EML4-ALKv1/pMX-iresCD8 in which cDNA for EMLA-ALK fusion protein v1 was integrated,...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase receptor(Homo sapiens (Human))
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Affinity DataIC50: 0.340nMAssay Description:A recombinant retrovirus was created from expression plasmid FLAG-EML4-ALKv1/pMX-iresCD8 in which cDNA for EMLA-ALK fusion protein v1 was integrated,...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Affinity DataIC50: 0.340nMAssay Description:A partial protein of only a kinase domain of FLT3 protein was purchased from Carna Biosciences Inc., Japan, and tests were conducted as in Test Examp...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Affinity DataIC50: 0.350nMAssay Description:A partial protein of only a kinase domain of FLT3 protein was purchased from Carna Biosciences Inc., Japan, and tests were conducted as in Test Examp...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Affinity DataIC50: 0.360nMAssay Description:A partial protein of only a kinase domain of FLT3 protein was purchased from Carna Biosciences Inc., Japan, and tests were conducted as in Test Examp...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Affinity DataIC50: 0.360nMAssay Description:A partial protein of only a kinase domain of FLT3 protein was purchased from Carna Biosciences Inc., Japan, and tests were conducted as in Test Examp...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase receptor(Homo sapiens (Human))
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Affinity DataIC50: 0.370nMAssay Description:A recombinant retrovirus was created from expression plasmid FLAG-EML4-ALKv1/pMX-iresCD8 in which cDNA for EMLA-ALK fusion protein v1 was integrated,...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Affinity DataIC50: 0.370nMAssay Description:A partial protein of only a kinase domain of FLT3 protein was purchased from Carna Biosciences Inc., Japan, and tests were conducted as in Test Examp...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Affinity DataIC50: 0.370nMAssay Description:A partial protein of only a kinase domain of FLT3 protein was purchased from Carna Biosciences Inc., Japan, and tests were conducted as in Test Examp...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase ROS(Homo sapiens (Human))
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Affinity DataIC50: 0.370nMAssay Description:A partial protein of only a kinase domain of ROS protein was purchased from Carna Biosciences Inc., Japan, and tests were conducted as in Test Exampl...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Affinity DataIC50: 0.390nMAssay Description:A partial protein of only a kinase domain of FLT3 protein was purchased from Carna Biosciences Inc., Japan, and tests were conducted as in Test Examp...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase ROS(Homo sapiens (Human))
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Affinity DataIC50: 0.400nMAssay Description:A partial protein of only a kinase domain of ROS protein was purchased from Carna Biosciences Inc., Japan, and tests were conducted as in Test Exampl...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase ROS(Homo sapiens (Human))
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Affinity DataIC50: 0.410nMAssay Description:A partial protein of only a kinase domain of ROS protein was purchased from Carna Biosciences Inc., Japan, and tests were conducted as in Test Exampl...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Affinity DataIC50: 0.410nMAssay Description:A partial protein of only a kinase domain of FLT3 protein was purchased from Carna Biosciences Inc., Japan, and tests were conducted as in Test Examp...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Affinity DataIC50: 0.440nMAssay Description:A partial protein of only a kinase domain of FLT3 protein was purchased from Carna Biosciences Inc., Japan, and tests were conducted as in Test Examp...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Affinity DataIC50: 0.460nMAssay Description:A partial protein of only a kinase domain of FLT3 protein was purchased from Carna Biosciences Inc., Japan, and tests were conducted as in Test Examp...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase receptor(Homo sapiens (Human))
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Affinity DataIC50: 0.490nMAssay Description:A recombinant retrovirus was created from expression plasmid FLAG-EML4-ALKv1/pMX-iresCD8 in which cDNA for EMLA-ALK fusion protein v1 was integrated,...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Affinity DataIC50: 0.490nMAssay Description:A partial protein of only a kinase domain of FLT3 protein was purchased from Carna Biosciences Inc., Japan, and tests were conducted as in Test Examp...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Affinity DataIC50: 0.5nMAssay Description:A partial protein of only a kinase domain of FLT3 protein was purchased from Carna Biosciences Inc., Japan, and tests were conducted as in Test Examp...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase ROS(Homo sapiens (Human))
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Affinity DataIC50: 0.510nMAssay Description:A partial protein of only a kinase domain of ROS protein was purchased from Carna Biosciences Inc., Japan, and tests were conducted as in Test Exampl...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Affinity DataIC50: 0.510nMAssay Description:A partial protein of only a kinase domain of FLT3 protein was purchased from Carna Biosciences Inc., Japan, and tests were conducted as in Test Examp...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase ROS(Homo sapiens (Human))
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Affinity DataIC50: 0.510nMAssay Description:A partial protein of only a kinase domain of ROS protein was purchased from Carna Biosciences Inc., Japan, and tests were conducted as in Test Exampl...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Affinity DataIC50: 0.510nMAssay Description:A partial protein of only a kinase domain of FLT3 protein was purchased from Carna Biosciences Inc., Japan, and tests were conducted as in Test Examp...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Affinity DataIC50: 0.520nMAssay Description:A partial protein of only a kinase domain of FLT3 protein was purchased from Carna Biosciences Inc., Japan, and tests were conducted as in Test Examp...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Affinity DataIC50: 0.560nMAssay Description:A partial protein of only a kinase domain of FLT3 protein was purchased from Carna Biosciences Inc., Japan, and tests were conducted as in Test Examp...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase ROS(Homo sapiens (Human))
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Affinity DataIC50: 0.580nMAssay Description:A partial protein of only a kinase domain of ROS protein was purchased from Carna Biosciences Inc., Japan, and tests were conducted as in Test Exampl...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase receptor(Homo sapiens (Human))
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Affinity DataIC50: 0.650nMAssay Description:A recombinant retrovirus was created from expression plasmid FLAG-EML4-ALKv1/pMX-iresCD8 in which cDNA for EMLA-ALK fusion protein v1 was integrated,...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase ROS(Homo sapiens (Human))
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Affinity DataIC50: 0.650nMAssay Description:A partial protein of only a kinase domain of ROS protein was purchased from Carna Biosciences Inc., Japan, and tests were conducted as in Test Exampl...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Affinity DataIC50: 0.660nMAssay Description:A partial protein of only a kinase domain of FLT3 protein was purchased from Carna Biosciences Inc., Japan, and tests were conducted as in Test Examp...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Affinity DataIC50: 0.720nMAssay Description:A partial protein of only a kinase domain of FLT3 protein was purchased from Carna Biosciences Inc., Japan, and tests were conducted as in Test Examp...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase receptor(Homo sapiens (Human))
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Affinity DataIC50: 0.770nMAssay Description:A recombinant retrovirus was created from expression plasmid FLAG-EML4-ALKv1/pMX-iresCD8 in which cDNA for EMLA-ALK fusion protein v1 was integrated,...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase ROS(Homo sapiens (Human))
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Affinity DataIC50: 0.780nMAssay Description:A partial protein of only a kinase domain of ROS protein was purchased from Carna Biosciences Inc., Japan, and tests were conducted as in Test Exampl...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase ROS(Homo sapiens (Human))
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Affinity DataIC50: 0.860nMAssay Description:A partial protein of only a kinase domain of ROS protein was purchased from Carna Biosciences Inc., Japan, and tests were conducted as in Test Exampl...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase ROS(Homo sapiens (Human))
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Affinity DataIC50: 0.860nMAssay Description:A partial protein of only a kinase domain of ROS protein was purchased from Carna Biosciences Inc., Japan, and tests were conducted as in Test Exampl...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase receptor(Homo sapiens (Human))
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Affinity DataIC50: 0.930nMAssay Description:A recombinant retrovirus was created from expression plasmid FLAG-EML4-ALKv1/pMX-iresCD8 in which cDNA for EMLA-ALK fusion protein v1 was integrated,...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase receptor(Homo sapiens (Human))
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Affinity DataIC50: 0.940nMAssay Description:A recombinant retrovirus was created from expression plasmid FLAG-EML4-ALKv1/pMX-iresCD8 in which cDNA for EMLA-ALK fusion protein v1 was integrated,...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Affinity DataIC50: 0.950nMAssay Description:A partial protein of only a kinase domain of RET protein was purchased from Carna Biosciences Inc., Japan. The phosphorylation activity toward a pept...More data for this Ligand-Target Pair
TargetTyrosine-protein kinase receptor(Homo sapiens (Human))
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Astellas Pharma Inc.; Kotobuki Pharmaceutical Co., Ltd.
US Patent
Affinity DataIC50: 0.990nMAssay Description:A recombinant retrovirus was created from expression plasmid FLAG-EML4-ALKv1/pMX-iresCD8 in which cDNA for EMLA-ALK fusion protein v1 was integrated,...More data for this Ligand-Target Pair